Colorectal Cancer
Guardant Health Raises Full-Year Guidance as Q3 Revenues Jump 34 Percent
The company said that overall test volume growth and an increase in insurance reimbursement for its Guardant360 test helped drive Q3 growth.
Top Five Articles on 360Dx Last Week: Qiagen Respiratory Test Cleared; Eurofins Acquisition; More
Last week, readers were most interested in a story about the FDA's clearance of Qiagen's QiaStat-Dx Respiratory Panel Mini syndromic multiplex qPCR test.
The researchers used publicly available data from companies such as Guardant Health, Exact Sciences, and Geneoscopy to determine possible effects of blood-based tests.
Exact Sciences Nabs FDA Approval for Cologuard Plus Assay
The stool-based test is the next-generation version of Exact's existing Cologuard test for colorectal cancer screening.
Geneoscopy Gets Lab Permit From New York State Department of Health
With the New York lab permit, the St. Louis-based company can now offer its ColoSense colon cancer screening test throughout the US.